Lysin Platform
Zeus™ - Discovery Platform
Zeus™ anti-bacterial lysin bio-informatics platform evaluates and optimizes the potential of thousands of first-in-class antimicrobial therapeutics for the precise augmentation of antimicrobial properties for commercial application.
Expedites precision antimicrobial discovery, enabling far more effective microbiome editing than existing approaches do. Holds almost 90 million candidate payloads within databases. Analyzed over 2.0 million input sources for endolysin candidates. Identified endolysins for over 70,000 taxa/candidate taxa of bacterial targets.
The platform has already successfully produced several validated lead lysins against difficult-to-target organisms.
Has the power to discover and develop payloads targeting virtually any bacterial species of interest. Gram-negative lysins identified to-date appear effective, even in the presence of human serum. Manufacturable at a low cost of goods. Particularly promising leads to target multiple difficult-to-treat vaginosis pathogens.
LysiThru™ – Lysin Screening
LysiThru™ is a proprietary discovery platform that allows the high-throughput identification and engineering of gram-positive and gram-negative lysins with commercial potential. High throughput creates a materially competitive advantage. The largest published library of screened lysin clones is about 940 clones. LysiThru™ has screened as many as 800 clones in a single day.
The platform has already been successful producing several lead lysins against difficult-to-target organisms. Several of the lead lysins are now in late stage pre-clinical development. A number of these lead lysins are against ESKAPE pathogens, including MDR gram-negative pathogens. The gram negative lysins created to-date appear effective, even in the presence of human serum, and are manufacturable at a low cost of goods.
This industry-leading high throughput system assures that Precisio will remain at the forefront of the industry.
